Agenebio Inc., of Baltimore, said it received two grant awards to advance approaches to slowing progression of mild cognitive impairment due to Alzheimer's disease from the National Institute of Aging and the National Institute of Neurological Disorders and Stroke. The awards will help support a phase III trial of AGB-101.